VSTM Shows Promise
VSTM's VS-7375 demonstrates clinical activity with favorable safety in Phase 1/2 trial for KRAS G12D-mutated solid tumors
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.